Objective: To evaluate whether generic substitution was associated with any difference in medical resource utilization for 5 widely used antiepileptic drugs (AEDs) in the United States.
generic to branded AEDs vs other chronicdisease drugs. [11] [12] [13] [14] [15] To our knowledge, few studies have evaluated the relationship between generic AED use and outcomes. This study investigates the association of generic AED use with all-cause and epilepsy-related medical resource utilization and injury risk in patients with epilepsy for 5 widely used AEDs in the United States: carbamazepine, gabapentin, phenytoin, primidone, and zonisamide. In addition, it addresses generic AED use in both stable and unstable patients since there may be different effects across groups. Understanding of outcomes resulting from generic substitution is important to inform treatment decisions in epilepsy management.
METHODS Data source. Health insurance claims from the
PharMetrics Patient-Centric database, comprising over 50 million managed-care lives from approximately 90 health care plans throughout the United States between January 2000 and October 2007, were used. Data elements include enrollment records, patient demographics, prescription drug dispensings (date of dispensing, dose, formulation, quantity of drug dispensed, intended treatment duration, and specialty of the provider), inpatient and outpatient medical services (date and place of service, e.g., hospital, emergency room [ER] , or medical clinic), International Classification of Diseases (ICD)-9 diagnosis codes, procedure codes (Current Procedural Terminology-4, Healthcare Common Procedure Coding System, or Revenue Center Codes), and physician specialty.
Study population. The study population was identified according to the following criteria: Ն18 years of age at the beginning of observation, Ն2 years of continuous health plan enrollment, a diagnosis of epilepsy (ICD-9: 345.x), nonfebrile convulsions (ICD-9: 780.3 or 780.39), or both, the dispensing of 1 of the 5 studied AEDs at least twice by the pharmacy, and Ն60 days of AED dispensing during the first 90 days of treatment.
The 5 studied AEDs (carbamazepine, gabapentin, phenytoin, primidone, and zonisamide) were chosen according to the following criteria: 1) a generic version was available during the study period and 2) data were available of Ն100 patients in each cohort (brand and generic). For gabapentin, only monotherapy patients were selected to exclude patients using it for nonepilepsy indications.
The study period began from the first AED dispensing until 30 days after the last day of drug supply, the end of health insurance eligibility, or the end of data availability, whichever occurred first. To ensure continuous AED use, data were censored at the first 30-day treatment gap.
Standard protocol approvals, registrations, and patient consents.
No approval was needed for this study.
Study design.
A retrospective open-cohort design was used to classify the duration of the observations into 2 mutually exclusive periods of brand and generic use of AEDs. Selected clinical outcome measures were compared during brand-and genericuse periods using a person-time approach. 16, 17 Incidence rates of health care utilization were calculated for prescriptions of other AEDs and non-AEDs, hospitalizations, outpatient visits (office and ER visits), and length of hospital stays.
To describe treatment patterns, switching rates were calculated. Generic switch was defined as a patient switching to a generic drug after having received a branded drug. Brand switch was defined as a patient switching to a branded drug after having received a generic drug. Switchback was defined as a patient who previously did a generic switch, and then switched back to the branded drug. Switch-in was defined as a patient switching to the studied drug from another AED, either brand or generic. Switch-out was defined as a patient switching from the studied drug to another AED. The number of generic versions of the studied drug dispensed was also calculated. AED polytherapy was defined as patients using at least 2 AEDs concomitantly at any time during the observation period.
Stable and unstable epilepsy. Study results were further stratified into stable vs unstable epilepsy groups. The stable group was operationally defined as patients with Յ2 outpatient services per year on average throughout the observation period and no ER visit associated with epilepsy or nonfebrile convulsions. All other patients were defined as having unstable epilepsy.
Statistical analysis. Patient characteristics and treatment
patterns. Frequency counts and percentages were used to describe categorical variables, while means and standard deviations were used for continuous variables. Statistical comparisons of characteristics between cohorts of stable vs unstable epilepsy patients were conducted using the Pearson 2 test for categorical variables and a 2-sided Student t test for continuous variables.
Health care resource utilization. All-cause (i.e., all events) and epilepsy-related (i.e., events associated with an epilepsy diagnosis, ICD codes 345.x, 780.3, 780.39) health care resource use were evaluated. Incidence rates of pharmacy and medical service utilization were calculated as the number of events divided by the number of person-years observed, and were compared between periods of branded vs generic use of AEDs using incidence rate ratios (IRR). The duration of prescriptions was normalized to 28 days to enable incidence rate comparisons.
Unadjusted IRR for generic vs branded use were generated using univariate Poisson regression models whereas adjusted IRR were generated using multivariate Poisson regression models. The covariates for adjustment included demographics (age, gender), comorbidities frequently associated with epilepsy identified during the first 180 days of observation period (brain tumors Time to first epilepsy-related event. Univariate (Kaplan-Meier) time-to-event analysis was conducted to compare medical service utilization over time during periods of continuous brand use vs generic use. Furthermore, multivariate (Cox proportional hazards model) time-to-event analyses were conducted to compare the occurrence of injuries (fracture: ICD-9 code: 800 -829; head injury: ICD-9 code: 850.x-854.x, 959.01, 800.x-804.x, 873.x; injury due to motor vehicle accident: ICD-9 code: E810 -E825) between periods of exclusive brand vs generic AED use. The outcome measures for these analyses were 1) risk of all-cause injury and 2) injuries related to epilepsy, i.e., ICD-9 code: 345.x, 780.3, or 780.39.
A 2-sided ␣ error of 0.05 was used to declare statistical significance. All statistical analyses were performed using SAS version 9.1 (SAS Institute, Inc., Cary, NC). Table 1 describes the demographic characteristics of the 33,625 studied patients. Users of phenytoin constituted the largest group (16,668 patients), whereas primidone (1,301 patients) and zonisamide (1,652 patients) represented the smallest cohorts. Mean patient ages ranged from 42.5 to 55.2 years; 44%-66% were women. The mean observation period was approximately 4 years, and patients were evenly distributed across regions. The most prevalent comorbidities were depression and other psychiatric conditions.
RESULTS Study population.
A total of 18,125 (54%) stable and 15,500 (46%) unstable patients were studied. Stable patients were slightly older than unstable patients (52.5 vs 49.1 years, p Ͻ 0.0001), with a higher proportion of women (52.4% vs 49.1%, p ϭ 0.0053). Stable patients were generally healthier based on comorbidity burden than unstable patients, with lower prevalence of brain tumors, stroke, anxiety, and other psychiatric conditions (all p values Ͻ0.05). Table 2 presents treatment patterns. The proportion of generic-only users tended to be greater for The highest proportions of switch-in and switch-out patients were found in the zonisamide group, followed by the primidone group. The proportion of stable patients was largest in gabapentin users (82.6%), followed by primidone (62.1%), carbamazepine (52.9%), phenytoin (48.2%), and zonisamide (40.1%). Among generic users, the proportion of patients receiving Ն2 different generic versions ranged from 6.8% of phenytoin users to 41.3% of zonisamide users over the study period. Of note, the stable population comprised less polytherapy users (25.8% vs 45.5%, p Ͻ 0.0001) and fewer switch-out patients (15.4% vs 25.1%, p Ͻ 0.0001) than the unstable group.
Health care resource utilization. Table 3 compares incidence rates of health care resource utilization between periods of branded vs generic use of AEDs. The unadjusted results indicated that periods of generic use were associated with significant increases in all-cause and epilepsy-related medical resource utilization, as compared to branded use of AEDs.
After adjusting for covariates, periods of generic AED use remained associated with increased rates of all-cause drug utilization (adjusted IRR [95% confidence interval (CI)] ϭ 1. 13 Abbreviation: AED ϭ antiepileptic drug. a Defined as Յ2 outpatient visits for epilepsy or nonfebrile seizures, no emergency room visit for epilepsy or nonfebrile seizure, and continuous usage of AED. b p Values tested the null hypothesis that the distribution was similar between the stable and unstable groups. c One-year generic switch, switchback, and brand switch rates were estimated with a Kaplan-Meier conditional probability approach. For all drugs, switchback rates were computed over a 1-year period following a generic switch. d For gabapentin, only monotherapy patients were selected to avoid the inclusion of patients using this medication for nonepilepsy indications. e Switch in was defined as a patient switching to the studied drug after being previously treated with another AED. Switch out was defined as a patient switching from the studied drug to another AED.
Neurology 74 May 18, 2010
For epilepsy-related medical resource use, observed differences in health care resource utilization between groups were similar, all showing higher utilization rates during generic-use periods ( Time-to-event analyses. Figure 1 illustrates the Kaplan-Meier curve for medical services used during periods of branded vs generic use. These results corroborate the health care resource utilization findings, indicating that relative risks of all medical service use during periods of generic AED use were consistently and significantly higher throughout the 4-year observation than during periods of brand use. Figure 2 illustrates adjusted HRs for the incidence of injuries, both all-cause and epilepsy-related. Generic-use periods were associated with increased risks of fracture, head injury, or motor vehicle accident injury ( DISCUSSION This retrospective study demonstrates that periods of generic AED use were associated with significantly higher all-cause and epilepsy-related medical resource utilization and risk of injury for 5 commonly prescribed AEDs in patients with epilepsy after controlling for confounding factors, even in patients characterized with stable epilepsy. Periods of generic AED use were associated with significantly higher overall utilization of prescription drugs (ϩ13%) and allcause medical services (hospitalizations: ϩ31%; length of hospital stays: ϩ33%; outpatient services: ϩ17%) compared to brand-use periods. Increases in health care utilization during generic-use periods were also demonstrated at the epilepsy-specific level, in terms of higher rates of hospitalization (ϩ24%) and outpatient visits (ϩ14%), as well as longer lengths of hospital stays (ϩ29%). Time-to-event analyses also revealed significantly greater risks of injuries during generic-use periods (all-cause injuries: ϩ22%; epilepsy-related injuries: ϩ23%).
Although causality cannot be formally proven in such an observational setting, we believe there are 2 main explanations for our findings. First, bioavailability differences may exist between branded and generic AEDs, which could generate negative health effects in patients with epilepsy. Such differences, if they exist, would be exacerbated by 2 facts: most AEDs have a narrow therapeutic index, and therapy failure in epilepsy can have deleterious consequences. Secondly, a negative placebo effect, i.e., experienced by patients as a result of knowingly receiving a drug subject to bad publicity, might also partly contribute to increased resource utilization or adverse effect reporting.
These results, based on a large US commercially insured population, are consistent with previous research conducted outside the United States comparing health care utilization by branded vs generic AEDs in epilepsy patients. Specifically, a Canadian study demonstrated that use of generic lamotrigine was associated with significant increases in AED and non-AED prescriptions dispensed (other AEDs: ϩ17%; non-AEDs: ϩ28%) and significantly higher utilization of medical services (medical visits: ϩ13%; length of hospital stays: ϩ49%). 11 Similar findings were also observed for the generic use of topiramate in Canada. 15 In a recent United States-based case-control study, patients with epilepsy receiving inpatient or emergency care had an 81% greater risk of having switched to a generic AED within the previous 6 months, compared to patients receiving only outpatient care without an inpatient or emergency visit. 14
Figure 1
Association of total medical services with the use of brand and generic antiepileptic drugs
This study adds to previously published research in several respects. First, it constitutes a wide-scale quantitative portrait of differences in medical utilization associated with generic substitution of AEDs in the United States. Aggregating claims data on 33,625 individuals with epilepsy and treated with 5 different AEDs, the present study covers a broader and more diversified population than previous comparable research. As such, the similarity of current results with those of past studies emphasizes the association of increased health care utilization with AED generic substitution.
We also evaluated whether stable epilepsy patients were differently affected by generic AED use compared to unstable patients. This distinction is important because these 2 different groups have different medical needs and challenges (e.g., seizure control, functional status, and quality of life). It was hypothesized that changes in medication may disturb the fine balance of control in either group to differential extent. Our operational definition of stable epilepsy (less than 2 seizure-related encounters in the prior 12 months) resulted in 56.2% being characterized as stable. Some might consider this definition overly conservative. However, interestingly, our results show that, even in stable patients, increases in health care resource utilization were demonstrated during generic-use periods and similar in magnitude and sig-nificance to the overall epilepsy sample with the exception of epilepsy-specific outpatient services because that was a component of the definition of stable epilepsy. This suggests that generic use may be associated with poor clinical outcomes despite the relative stability of the patient and that clinicians may need to consider this when managing patients with low levels of epilepsy-related health care utilization. The risk of epilepsy-related injury among stable patients was notably high as well, although this may be attributed to the variation from the small sample size, as indicated by the wide CI.
An advantage of this study design is the possibility of evaluating medical switching patterns in a longitudinal fashion with the use of person-year data. This approach is most appropriate in observational studies where each patient is observed for a different length of time, and for periods with nonuniform beginning and end points. 17 Also, controlling for the different studied AEDs captures the statistical association of specific drugs, hence allowing the measured generic difference to represent an association across the entire therapeutic class, and not one simply influenced by a particular drug. This procedure controls for the fact that phenytoin comprised about half of the study sample. A sensitivity analysis revealed that similar outcomes were observed with or without phenytoin.
Figure 2
Association of all-cause and epilepsy-related injuries during generic vs brand use periods These adjusted ratios are compared to an adjusted hazard ratio of 1.00 for brand use. All adjusted hazard ratios depicted above are significant at p Ͻ 0.05. The adjusted hazard ratios and confidence intervals were estimated using multivariate Cox regression models, controlling for the following confounding factors: demographics (gender, age), comorbidities (brain tumors, stroke, depression, anxiety, bipolar disorders, other psychiatric conditions, and migraine), treatment characteristics (stable epilepsy, polytherapy, and presence of switch-in), regions (Northeast, South, Midwest, and West), and antiepileptic drugs.
Another consideration in the study design is that data were censored if there were any 30-day treatment gaps, to ensure continuous brand or generic use, resulting in only adherent patients being captured. In previous studies, nonadherence has been associated with significant increases in morbidity, mortality, and economic costs. [18] [19] [20] [21] [22] These findings indicate that nonadherence would likely increase the incidence of observed outcomes during both brandand generic-use periods.
There are several limitations in the present study, primarily inherent in conducting research with administrative claims data. Administrative claims data do not include some relevant potential confounding factors, such as disease severity. They may also present inaccuracies in coding of diagnoses and procedures. Additionally, pharmacy claims data do not provide information on whether drugs dispensed were actually taken according to prescribed instructions and, consequently, no assessment can be made of the actual consumption of medication by the patient. 23 Although our study has shown an association between generic AED treatment and increased rates of health care utilization, it has not, strictly speaking, established a causal link. Other unobserved characteristics might dilute the association. For example, patients with less health care utilization may be less likely to have contact with the health care system and therefore have less opportunity to switch to generic AEDs. Other variables, such as plasma concentration and bioequivalence, were not available and hence were not adjusted for. Finally, these results apply only to the studied AEDs, which represented 5 widely prescribed AEDs in the United States, but it is possible that the results may not be generalizable to other AEDs or generic formulations.
Despite these limitations, our study suggests that even though generic and branded AEDs are deemed bioequivalent under current regulations, some differences appear to exist in the extent of health care utilization in both stable and unstable patients when they are changed between these formulations. It is important that physicians and patients together understand the factors associated with generic substitution of AEDs. A longitudinal clinical study is warranted to contribute to understanding differences between generic and branded AEDs.
